Predilife S.A.

Paris Stock Exchange ALPRE.PA

Predilife S.A. EBIT Margin for the year ending December 31, 2023: -1,208.10%

Predilife S.A. EBIT Margin is -1,208.10% for the year ending December 31, 2023, a 0.13% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Predilife S.A. EBIT Margin for the year ending December 31, 2022 was -1,209.72%, a 51.17% change year over year.
Predilife S.A. EBIT Margin for the year ending December 31, 2021 was -2,477.34%, a 48.83% change year over year.
Predilife S.A. EBIT Margin for the year ending December 31, 2020 was -4,841.66%, a 54.49% change year over year.
Predilife S.A. EBIT Margin for the year ending December 31, 2019 was -10,638.30%, a -201.38% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

Paris Stock Exchange: ALPRE.PA

Predilife S.A.

CEO	Mr. Stephane Ragusa
IPO Date	Dec. 21, 2018
Location	France
Headquarters	39, Rue Camille Desmoulins
Employees	18
Sector	Consumers Staples
Industries Personal Care 3D Printing Biotechnology Clinical Trials Cosmetics Dental Care Medical Instruments Pharmaceuticals

Description

Predilife S.A. develops and sells medical techniques and mathematical models. The company provides prevention and breast check-up tests. Its products include MammoRisk, a test for predicting the development of breast cancer based on the patient's individual risk; and DenSeeMammo, a breast density measurement software, as well as a medical device for the prediction of prostate cancer risk. Predilife S.A. was founded in 2004 and is headquartered in Villejuif, France.

Key trends

Past 5 years